Gemtuzumab ozogamicin: First clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis

Keyphrases

• Relapsed or Refractory 100%
• Gemtuzumab Ozogamicin 100%
• Relapsed or Refractory Acute Myeloid Leukemia 100%
• Clinical Experience 100%
• Compassionate Use 100%
• Acute Myeloid Leukemia 50%
• Stem Cell Transplantation 37%
• CD33 37%
• Complete Remission 25%
• Pediatric 12%
• Clinical Efficacy 12%
• Regeneration 12%
• Monotherapy 12%
• Leukemia Patients 12%
• Mucositis 12%
• Platelets 12%
• Venous Disease 12%
• Platelet Recovery 12%
• Further Treatment 12%
• Hematotoxicity 12%
• Phase 1 Study 12%
• Stem Cell Leukemia 12%
• Hypotension 12%
• Mylotarg 12%
• Bone Marrow Blast 12%
• Durable Response 12%
• Remission Induction 12%
• Hyperbilirubinemia 12%
• Post-remission Therapy 12%
• Transaminase Elevations 12%

Medicine and Dentistry

• Acute Myeloid Leukemia 100%
• Compassionate Use 100%
• Gemtuzumab Ozogamicin 100%
• Stem Cell Therapy 33%
• Platelet 22%
• Pediatrics 11%
• Leukemia 11%
• Infection 11%
• Side Effect 11%
• Mucositis 11%
• Monotherapy 11%
• Transplantation 11%
• Vein Occlusion 11%
• Spontaneous Remission 11%
• Hypotension 11%
• Hyperbilirubinemia 11%
• Transaminase 11%

Pharmacology, Toxicology and Pharmaceutical Science

• Acute Myeloid Leukemia 100%
• Gemtuzumab Ozogamicin 100%
• Remission 33%
• Monotherapy 11%
• Leukemia 11%
• Infection 11%
• Side Effect 11%
• Mucosa Inflammation 11%
• Hypotension 11%
• Vein Occlusion 11%
• Aminotransferase 11%
• Hyperbilirubinemia 11%